Open AccessThe DLBCL90 gene‐expression assay identifies double‐hit lymphomas with high sensitivity in patients from two phase II clinical trials with high‐risk diffuse large B‐cell lymphoma
Author(s) -
Isaksen Kathrine T.,
Beiske Klaus,
Smeland Erlend B.,
Jørgensen Judit,
Brodtkorb Marianne,
Myklebust June Helen,
Jerkeman Mats,
Meriranta Leo,
KarjalainenLindsberg MarjaLiisa,
Leppä Sirpa,
Scott David W.,
Holte Harald,
Blaker Yngvild Nuvin
Publication year - 2021
Publication title -
ejhaem
Language(s) - English
Resource type - Journals
ISSN - 2688-6146
DOI - 10.1002/jha2.109
Subject(s) - bcl6 , lymphoma , vincristine , diffuse large b cell lymphoma , population , oncology , fluorescence in situ hybridization , medicine , rituximab , not otherwise specified , chop , cyclophosphamide , cancer research , pathology , biology , germinal center , b cell , immunology , chemotherapy , gene , antibody , genetics , environmental health , chromosome